228 related articles for article (PubMed ID: 30568462)
21. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
22. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
23. Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis.
Xu L; Jiang W; Li W; Guo C; Luo L; Gao Y; Cao Y
Exp Ther Med; 2022 Sep; 24(3):575. PubMed ID: 35949321
[TBL] [Abstract][Full Text] [Related]
24. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
25. Fulvestrant in advanced breast cancer: evidence to date and place in therapy.
Boér K
Ther Adv Med Oncol; 2017 Jul; 9(7):465-479. PubMed ID: 28717399
[TBL] [Abstract][Full Text] [Related]
26. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
27. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
28. A Review of Fulvestrant in Breast Cancer.
Nathan MR; Schmid P
Oncol Ther; 2017; 5(1):17-29. PubMed ID: 28680952
[TBL] [Abstract][Full Text] [Related]
29. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
30. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
Schmid P; Zaiss M; Harper-Wynne C; Ferreira M; Dubey S; Chan S; Makris A; Nemsadze G; Brunt AM; Kuemmel S; Ruiz I; Perelló A; Kendall A; Brown J; Kristeleit H; Conibear J; Saura C; Grenier J; Máhr K; Schenker M; Sohn J; Lee KS; Shepherd CJ; Oelmann E; Sarker SJ; Prendergast A; Marosics P; Moosa A; Lawrence C; Coetzee C; Mousa K; Cortés J
JAMA Oncol; 2019 Nov; 5(11):1556-1564. PubMed ID: 31465093
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.
Rocca A; Maltoni R; Bravaccini S; Donati C; Andreis D
Cancer Manag Res; 2018; 10():3083-3099. PubMed ID: 30214302
[TBL] [Abstract][Full Text] [Related]
32. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
34. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
36. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
37. Cyclin‑dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor‑positive breast cancer patients: A systematic review and meta‑analysis of randomized clinical trials.
Ramos-Esquivel A; Hernández-Romero G; Landaverde DU
Cancer Treat Res Commun; 2020 Apr; 23():100175. PubMed ID: 32361352
[TBL] [Abstract][Full Text] [Related]
38. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
39. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.
Lin M; Chen Y; Jin Y; Hu X; Zhang J
J Cancer; 2020; 11(24):7127-7136. PubMed ID: 33193875
[No Abstract] [Full Text] [Related]
40. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
Kümler I; Knoop AS; Jessing CA; Ejlertsen B; Nielsen DL
ESMO Open; 2016; 1(4):e000062. PubMed ID: 27843622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
